You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CDK 4/6

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Different treatment regimens following progression on CDK4/6 inhibitors.
  • (no location specified)
Sep 5, 2023

CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast

Not yet recruiting
  • Breast Cancer
  • CDK4/6 inhibitor
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

Recruiting
  • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
  • dalpiciclib; fluvestrant; compound gossypol acetate tablets
  • Hangzhou, Zhejiang, China
    zhejiangCH
Nov 9, 2023

Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)

Recruiting
  • Locally Advanced Breast Cancer
  • Hormone Receptor Positiveļ¼ŒHER2-negative Breast Cancer
  • Jinan, Shandong, China
    Breast Cancer Center, Shandong Cancer Hospital and Institute
Apr 11, 2023

Breast Cancer Trial in Baltimore (Endocrine Therapy and a CDK 4/6 inhibitor)

Recruiting
  • Breast Cancer
  • Endocrine Therapy and a CDK 4/6 inhibitor
  • Baltimore, Maryland
    Johns Hopkins University
Jul 18, 2022

Cancer Trial in Boston (Abemaciclib)

Recruiting
  • Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 9, 2023

Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality

Recruiting
  • Breast Cancer Stage IV
  • comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
  • Mansoura, Dakahlia, Egypt
    Oncology center mansoura university
Jan 1, 2023

Advanced Breast Cancer Trial in Lebanon (Fulvestrant, Neratinib, Alpelisib)

Not yet recruiting
  • Advanced Breast Cancer
  • Lebanon, New Hampshire
    Dartmouth Hitchcock Medical Center
Jun 28, 2023

Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

Recruiting
  • Neurofibromatosis 1
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)

Not yet recruiting
  • Advanced HR+ HER2 Negative Breast Carcinoma
  • (CDK)4/6 inhibitor
  • (no location specified)
Sep 27, 2022

Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

Not yet recruiting
  • Estrogen-receptor-positive Breast Cancer
  • +3 more
  • elacestrant, palbociclib, abemaciclib, ribociclib
  • Chicago, Illinois
    Northwestern University
Sep 25, 2023

Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)

Not yet recruiting
  • Hormone Receptor-positive Advanced Breast Cancer
  • chidamide combined with fulvestrant
  • (no location specified)
Mar 28, 2023

Breast Cancer Trial (RP-6306, Gemcitabine, Observation)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Jan 26, 2023

Learn About Use and Effects of CDK4/6 Inhibitors in Canadian

Active, not recruiting
  • Breast Cancer
    • Kirkland, Quebec, Canada
      Pfizer Canada
    Mar 5, 2023

    Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)

    Recruiting
    • Breast Cancer Metastatic Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Feb 26, 2023

    Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

    Not yet recruiting
    • Breast Cancer
    • +3 more
    • Miami, Florida
      University of Miami
    Apr 12, 2023

    CYP3A4*22 Trial (Palbociclib 125Mg Tab, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG Oral Tablet)

    Not yet recruiting
    • CYP3A4*22
    • Palbociclib 125Mg Tab
    • +2 more
    • (no location specified)
    Jan 10, 2023

    Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)

    Recruiting
    • Breast Cancer Metastatic Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Feb 26, 2023

    Breast Cancer Trial in Boston, Danvers (Ribociclib, Endocrine therapy)

    Recruiting
    • Breast Cancer
    • Boston, Massachusetts
    • +2 more
    Jan 6, 2023

    Tumors Trial in Seoul (abemaciclib+paclitaxel)

    Active, not recruiting
    • Tumors
    • Seoul, Korea, Republic of
      Severance Hospital
    May 30, 2022

    Breast Cancer, Advanced Breast Cancer Trial in Shanghai (Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and

    Not yet recruiting
    • Breast Cancer
    • Advanced Breast Cancer
    • Everolimus 10 mg
    • +2 more
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Jul 14, 2023

    Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)

    Not yet recruiting
    • Breast Cancer
    • Tianjin, China
      Tianjin Cancer Hospital
    Mar 28, 2023

    Breast Cancer Trial (Abemaciclib, Letrozole)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    Nov 14, 2023

    Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy

    Recruiting
    • Advanced Breast Cancer
    • The combination of Dalpiciclib with physician-selected endocrine therapy
    • Chemotherapy selected by the physician
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    May 22, 2023

    Metastatic Breast Cancer Trial (Elacestrant)

    Not yet recruiting
    • Metastatic Breast Cancer
    • (no location specified)
    Oct 24, 2022